19.37
+0.805(+4.34%)
Currency In USD
Address
611 Gateway Boulevard
South San Francisco, CA 94080
United States of America
Phone
628-229-9277
Website
Sector
Healthcare
Industry
Biotechnology
Employees
163
First IPO Date
February 03, 2023
| Name | Title | Pay | Year Born |
| Dr. Raymond C. Stevens Ph.D. | Chief Executive Officer & Director | 982,493 | 1964 |
| Dr. Yingli Ma Ph.D. | Chief Technology Officer | 497,585 | 1974 |
| Mr. Jun S. Yoon | Co- Founder, Chief Financial Officer & Secretary | 627,645 | 1978 |
| Dr. Blai Coll M.D., Ph.D. | Chief Medical Officer | 650,088 | 1974 |
| Dr. Xichen Lin Ph.D. | Chief Scientific Officer | 664,009 | 1974 |
| Mr. Bob Gatmaitan | Senior Vice President of People | 0 | N/A |
| Mr. Tony Peng | Senior Vice President of Legal | 0 | N/A |
| Ms. Lani Ibarra | Senior Vice President of Clinical Development Operations | 0 | N/A |
| Dr. Hui Lei Ph.D. | Senior Vice President of Chemistry | 0 | N/A |
| Dr. Fang Zhang Ph.D. | Executive Vice President & Head of Biology | 0 | N/A |
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.